Mell Welborn, MD
Vascular Surgery · Huntsville, ALNPI 1093763310
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Endologix LLC accounts for 60.0% of it on its own, with 26 other manufacturers making up the rest.
Across 156 payments — averaging $91.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Endologix LLC$9K
- Musculoskeletal Transplant Foundation Inc.$2K
- Penumbra, Inc.$1K
- Cook Medical LLC$783
- Silk Road Medical, Inc.$427
- Medtronic$358
- plus $1K from 21 others
What the payments were for
- Consulting fees$5,30037%
- Travel & lodging$1,2709%
- Food & beverage$7,74154%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Endologix LLC | 30 | $8,587 |
| Musculoskeletal Transplant Foundation Inc. | 4 | $1,662 |
| Penumbra, Inc. | 2 | $1,206 |
| Cook Medical LLC | 41 | $783 |
| Silk Road Medical, Inc. | 5 | $427 |
| Medtronic | 18 | $358 |
| Kerecis Limited | 7 | $281 |
| Inari Medical, Inc. | 4 | $144 |
| Johnson & Johnson(2 entities) | 8 | $126 |
| Lemaitre Vascular, Inc. | 3 | $113 |
| Smith+Nephew | 4 | $78 |
| W. L. Gore & Associates, Inc. | 5 | $78 |
| Cagent Vascular Inc | 1 | $73 |
| Polynovo North America LLC | 4 | $70 |
| E.r. Squibb & Sons, L.L.C. | 4 | $69 |
| Terumo Medical Corporation | 2 | $43 |
| Baxter Healthcare | 2 | $30 |
| Boston Scientific | 2 | $27 |
| Medela LLC | 2 | $25 |
| Abbott | 1 | $24 |
| Bard Peripheral Vascular, Inc. | 1 | $19 |
| AbbVie | 1 | $17 |
| Pfizer | 1 | $17 |
| Acell, Inc. | 1 | $15 |
| LSI Solutions Inc | 1 | $14 |
| Tactile Systems Technology Inc | 1 | $12 |
| EKOS Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AFX$2,188
- AFX2 Bifurcated Endograft System$2,159
- Alto Abdominal Stent Graft System$2,150
- Indigo System$1,206
- ENROUTE Transcarotid Neuroprotection System$475
- Ovation$388
- ENROUTE Transcarotid Stent$301
- ENDOCROSS Device$195
- Torus Stent Graft System$195
- ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$174
- Zenith$123
- Cook Medical AAA$115
How this compares
$14,311 in reported general payments places this provider in the 80th percentile of 61 vascular surgery providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 74 | $41,939 |
| XareltoRivaroxaban | 23 | $22,170 |
| ClopidogrelClopidogrel Bisulfate | 173 | $1,933 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 63 | $612 |
| Cilostazol | 22 | $548 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 25 | $400 |
| Tramadol Hcl | 11 | $62 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $17 | $41,93974 claims |
| Johnson & JohnsonXarelto | $126 | $22,17023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 61 vascular surgery providers in Alabama.
Other vascular surgery in Huntsville
- Andrew KnottHuntsville$76K
- Marco CioppiHuntsville$21K
- Benjamin ShepherdHuntsville$13K
- Ronny JohnsonHuntsville$9K
- Tracy LoweryHuntsville$209
- Rick RobertsHuntsville$131
- Albert PacificoBirmingham$5.1M
- Brian SellersMontgomery$71K
- Peter PonsFlorence$54K
- Benjamin PearceBirmingham$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.